Skip to main content

Table 1 Percentages of EGI-1 in each phase of the cell cycle after 48 hours of exposure to different dosages of rapamycin

From: Tumor growth effects of rapamycin on human biliary tract cancer cells

Group Apoptosisa G0/G1 phase G2 + M phase S phase
  Mean ±SE P b Mean ±SE P b Mean ±SE P b Mean ±SE P b
control 0.24 0.04   32.56 1.01   22.44 0.52   25.44 0.85  
rapa 1 ng/mL 0.28 0.02 0.33 35.98 1.21 0.55 21.24 0.35 0.085 17.96 0.23 <0.001
rapa 5 ng/mL 0.30 0.02 0.21 38.77 1.28 <0.05 22.21 0.26 0.70 19.97 0.44 <0.001
rapa 10 ng/mL 0.52 0.04 <0.05 37.09 0.50 <0.05 24.45 0.70 <0.05 15.88 0.29 <0.001
rapa 20 ng/mL 0.55 0.04 <0.05 36.75 1.32 <0.05 23.31 0.45 0.23 14.56 0.33 <0.001
rapa 50 ng/mL 0.42 0.05 <0.05 33.16 0.44 0.60 26.05 0.14 <0.05 16.15 0.37 <0.001
  1. Cell cycle analysis of EGI-1 and TFK-1 cell lines 48 hours after treatment with rapamycin at doses of 1, 5, 10 and 20 ng/mL, with 5-bromo-2′-deoxyuridine and 7-aminoactinomycin D staining aSub G1-region, indicating cells with small DNA fragments, a typical feature of apoptosis; bt-test was performed; while a Levene test was performed in case of unequal variances, P <0.05 was considered significant. Rapa: rapamycin; SE: standard error of the mean.